AsclepiX Therapeutics

📍 Baltimore, United States👥 13 employees💰 Last funded Jun 2020
Biotechnology🌐 asclepix.com
Website LinkedIn
FRAUD ALERT: AsclepiX is aware of individuals representing job postings that are not legitimate positions. AsclepiX is NOT hiring at this time. AsclepiX Therapeutics is a clinical-stage biopharmaceutical company leveraging computational biology from Johns Hopkins to identify and develop peptides for improved treatments of retinal diseases. Our lead candidate, AXT107, inhibits pro-angiogenic vascular endothelial growth factor receptor 2 (VEGFR2) and activates the vessel stabilizing receptor tyrosine kinase (Tie2), the two validated pathways for the treatment of retinal vascular diseases.
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in AsclepiX Therapeutics?
AsclepiX Therapeutics has 1 investors on record on gritt.io.
When did AsclepiX Therapeutics last raise funding?
The most recent investment in AsclepiX Therapeutics recorded on gritt.io was in June 2020.
What industry is AsclepiX Therapeutics in?
AsclepiX Therapeutics operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is AsclepiX Therapeutics based?
AsclepiX Therapeutics is headquartered in Baltimore, United States.